Skip to main content
Fig. 2 | Orphanet Journal of Rare Diseases

Fig. 2

From: Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective

Fig. 2

Median blood Phe levels of 11 patients with PKU taking L-AA versus CGMP-AA (last ANSE) with different percentages of contribution to the total protein substitute. CGMP-AA, casein glycomacropeptide supplements; L-AA, phenylalanine-free L-amino acid supplements; Phe, phenylalanine. Dashed line: target level of 480 µmol/L > 12 years. The number below each pair of bars represents Patient ID

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172